Ted Torphy.jpg
Jeff Edelson.jpg
Scott Oakes.jpeg

Ted Torphy, Chairman & Manager
Ted Torphy, PhD, is the Chief Executive Officer & Chief Scientific Officer of BioMotiv and Chair of the Cystic Fibrosis Foundation Therapeutics, Inc. Dr. Torphy brings over 30 years of experience in the pharmaceutical industry, including at Johnson & Johnson and SmithKlineBeecham, with a successful record in both small-molecule and large-molecule drug discovery.


Mark Chin, Manager
Mark Chin is an Investment Manager at Arix Bioscience, an investment firm focused on the biotechnology space.  Mark was previously a Principal at Longitude Capital, where he focused on investments in private and public biotechnology and medical technology companies.  Prior to Longitude, he was a Consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies.  Prior to BCG, Mark worked in Corporate Development at Gilead Sciences and Market Planning at Genentech.  Mark has a MBA from The Wharton School at the University of Pennsylvania, a MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.


Jeff Edelson, Manager
Dr. Jeff Edelson has more than 30 years of drug development experience, having served in senior clinical R&D roles for several biotech and pharmaceutical firms including SmithKline Beecham, Therion Biologics, GlaxoSmithKline, Aventis and Johnson and Johnson Pharmaceutical Research and Development, where he was most recently the Therapeutic Area Head of Novel Therapeutics.  He has experience developing immuno-oncology products, including cancer vaccines, as well as products for pulmonary, immunology, neurology, and therapeutic oncology across all phases of development. Dr. Edelson earned his MD at the University of Toronto.


Satish Jindal, Manager
Satish Jindal, PhD, is BioMotiv’s Managing Director. Most recently, Dr. Jindal served as CEO of Allied-Bristol Life Sciences (ABLS). Prior to ABLS, he served as a Vice President at Bristol-Myers Squibb (BMS) and Managing Director of the Biocon-Bristol-Myers Squibb Research Center (BBRC) in Bangalore, India. During his tenure at BMS, he partnered with Allied Minds and BMS to create the unique accelerator model, ABLS.

Dr. Jindal has extensive experience in forming and building biotechnology companies, including Vedantra Inc., an immunotherapy company that he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology (MIT); Verastem Inc., a NASDAQ-listed cancer stem cell company that he co-founded with researchers from the Whitehead Institute, the Broad Institute and MIT; and NeoGenesis Inc., a drug discovery company that was acquired by Schering-Plough in 2005.He also served as Vice President and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts, and worked in Business Development at UCB Pharma in the UK.

Dr. Jindal completed his postdoctoral work at Whitehead Institute for Biomedical Research at MIT and McMaster University in Hamilton, Ontario, Canada. He obtained a PhD in Biochemistry from Punjab University in India.


Scott Oakes, MD, Manager
Dr. Oakes is a Professor of Pathology and member of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Oakes earned his medical degree from the University of Connecticut, Farmington, CT, and completed his residency in anatomic pathology at Brigham and Women's Hospital, Boston. Following residency, he completed a 5-year postdoctoral fellowship in cell biology at Dana-Farber Cancer Center Institute and Harvard Medical School, Boston, MA, where he studied the regulation of the mitochondrial apoptotic pathway. Dr. Oakes was awarded a Howard Hughes Medical Institute Early Career Physician Scientist Award, and is an American Cancer Society Research Scholar, a Harrington Discovery Institute Scholar-Innovator, and an inductee of the American Society of Clinical Investigation. 


Tim Pelura, PhD, Manager

Dr. Pelura is a serial life science entrepreneur with over 40 years of experience in the pharmaceutical, biotech, and medical device industries and has been pivotal in the development of several new drugs and devices spanning numerous therapeutic areas.

Dr. Pelura has enjoyed a long history of growing early/idea stage life science companies through various financing strategies to well-capitalized, successful companies.  His previous positions include CEO of Surpass, Inc., a preclinical CRO; Chairman, President & CEO of Immunome, an antibody platform company; CEO of Promedior, a product-focused biotech company developing novel therapeutics for the treatment of fibrotic disorders and diseases; Chief Scientific Officer for Kereos, a biopharma company focusing on oncology, cardiology, and molecular imaging; President and COO of Provasis Therapeutics, a developer of interventional neurosurgical devices; executive R&D positions at Neuron Therapeutics and Alliance Pharmaceutical Corp; and various positions at Pharmacia, a pharmaceutical and biotech company.   

Dr. Pelura is also pivotally involved in several non-profit, regional and national life science initiatives and holds a PhD in chemistry from Rutgers University.